Drug Patents owned by Sandoz Inc

1. Drug name - ANGIOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7598343 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(5 years from now)

US7582727 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(5 years from now)

US7582727

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(6 years from now)

US7598343

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(6 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL INJECTABLE;INTRAVENOUS Prescription

2. Drug name - QOLIANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117 SANDOZ INC Topical brimonidine tartrate formulations that lack chlorine dioxide
Aug, 2025

(2 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.15% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in